A University of Oxford group and the British-Swedish pharmaceutical company AstraZeneca reported Monday that their coronavirus vaccine candidate, on which the U.S. and European governments have placed substantial bets, was shown in early-stage human trials to be safe and to stimulate a strong immune response.
An experimental coronavirus vaccine being developed by pharmaceutical giant Pfizer and the German firm BioNTech triggered stronger immune responses in recipients than those seen in people recovering from a natural infection in a small study published online Wednesday.
In the global race to beat back the coronavirus pandemic, scientists in Britain, Germany, China and the United States are pushing to develop, and possibly manufacture, vaccines in a completely new way. This promising — but unproven — new generation of vaccine technologies is based on deploying a tiny snip of genetic code called messenger RNA to trigger the immune system. It has never before been approved for use.
Those decades of research into HIV have taught scientists an enormous amount about the immune system, honed vaccine technologies now being repurposed against the coronavirus and created a worldwide infrastructure of clinical trial networks that can be pivoted from HIV to the pathogen that causes the disease covid-19.
Experts say testing is a vital component to controlling the outbreak, but one test result still isn’t a green light to visit vulnerable friends or family members. The nature of covid-19, the time it takes for someone to develop symptoms and the varied ways the virus affects people make each test a snapshot in time more than a definitive answer.
This is a report from a leaked government report. Its is not sure how these predictions are made, and whether it is because of reopening. The white house officials have been relying on other models (than CDC) to make decisions on reopening. The estimates here are based on premature relaxation of restrictions.
People with underlying medical conditions such as heart disease and diabetes were hospitalized six times as often as otherwise healthy individuals infected with the novel coronavirus during the first four months of the pandemic, and they died 12 times as often, according to a federal health report Monday.
A lab outside Rome took “seed stock” produced at Oxford. Now U.S. and European officials are showing signs of support. That vaccine, like all the others designed to combat the pandemic, remains unproved. But it is further along in the trial process than the others, and it has turned into the West’s best — and perhaps only — chance to have a viable vaccine before the end of the year.
A mutation that seems trivial could be making the virus spread more easily. At least four laboratory experiments suggest that the mutation makes the virus more infectious, although none of that work has been peer-reviewed. Another unpublished study led by scientists at Los Alamos National Laboratory asserts that patients with the G variant actually have more virus in their bodies, making them more likely to spread it to others.
Shutdown orders prevented about 60 million novel coronavirus infections in the United States and 285 million in China, according to a research study published Monday that examined how stay-at-home orders and other restrictions limited the spread of the contagion.